ArticleFrontiers in pharmacology2020
Access and Benefit Sharing Under the Nagoya Protocol-
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Marine Antimicrobial Peptides: From Ocean Biodiversity to Genome Mining, Multi-Omics Discovery, and Biotechnological Innovation in the Battle Against Antimicrobial Resistance.Probiotics and antimicrobial proteins · 2026Review
- Natural Products in Cancer Research: Mechanistic Advances, Translational Challenges, and the Emerging Role of Chilean Biodiversity.Molecules (Basel, Switzerland) · 2026Review
- Exploring the global mosaic of medicinal plant databases: unveiling nature's pharmacopoeia.Natural products and bioprospecting · 2026Review
- Channeling ancestral knowledge into production: from Ecuadorian curare to a shared-benefit model that breaks Indigenous poverty.Frontiers in public health · 2026Article
- Policy in Practice: How to do the Nagoya Protocol: common misconceptions, challenges and best practices for access and benefit-sharing compliance.Sustainable microbiology · 2026Article
- Exploring Colombian medicinal flora used in indigenous and campesino health systems for neuropsychiatric disorders and neuropharmacological potential: an ethnopharmacological review.Frontiers in pharmacology · 2026Review
- Friends with benefits: What constitutes a 'benefit' in Access and Benefit Sharing (ABS) for plant genetic resources?Agriculture and human values · 2026Article
- A new indicator for the Kunming-Montreal Global Biodiversity Framework: Capturing non-monetary benefit data from access and benefit-sharing agreements.Bioscience · 2025Article
- Taxonomic, Physiological, and Biochemical Characterization ofPlants (Basel, Switzerland) · 2024Article
- Article
- Technology Readiness Level Roadmap for Developing Innovative Herbal Medicinal Products.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Traditional, complementary and integrative healthcare: global stakeholder perspective on WHO's current and future strategy.BMJ global health · 2023Review
- Editorial: Toward a better understanding and application of benefit sharing in genomic and global health research.Frontiers in genetics · 2023Article
- Specimen sharing for epidemic preparedness: Building a virtual biorepository system from local governance to global partnerships.PLOS global public health · 2023Article
- Modern venomics-Current insights, novel methods, and future perspectives in biological and applied animal venom research.GigaScience · 2022Article
- Article
- Balancing openness with Indigenous data sovereignty: An opportunity to leave no one behind in the journey to sequence all of life.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Operationalizing "One Health" as "One Digital Health" Through a Global Framework That Emphasizes Fair and Equitable Sharing of Benefits From the Use of Artificial Intelligence and Related Digital Technologies.Frontiers in public health · 2022Article
- Benefit sharing: Why inclusive provenance metadata matter.Frontiers in genetics · 2022Article
- Bioprospecting for Antibacterial Drugs: a Multidisciplinary Perspective on Natural Product Source Material, Bioassay Selection and Avoidable Pitfalls.Pharmaceutical research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobal challenges related to access and benefit sharing (ABS) of biological resources have become a key concern in the area of research on herbal medicines, ethnopharmacology, drug discovery, and the development of other high value products for which Intellectual Property protection can be secured. While the Convention on Biological Diversity (CBD, Rio 1992) has been recognized as a huge step forward, the implementation of the Nagoya Protocol (NP) and of new forms of collaboration often remain unresolved, especially in the context of "the fair and equitable sharing of benefits arising from the utilization of genetic resources" (Convention on Biological Diversity, 2011). The vision and the specific implementation of this international treaty vary from country to country, which poses additional challenges.
aimsUsing a case study approach, in this analysis we aim at understanding the specific opportunities and challenges for implementing international collaborations regarding ABS in six Latin American countries-Chile, Colombia, Guatemala, México, Panama, and Peru. Based on that analysis, we provide recommendations for the path ahead regarding international collaborations under ABS agreements in ethnopharmacological research. RESULTS AND DISCUSSIONS: The implementation of the NP varies in the six countries; and while they are all rich in biodiversity, access and benefit sharing mechanisms differ considerably. There is a need to engage in a consultation process with stakeholders, but this has often come to a halt. Institutional infrastructures to implement national policies are weak, and the level of knowledge about the NP and the CBD within countries remains limited.
conclusionsDifferent policies in the six countries result in very diverse strategies and opportunities relating to the equitable use of biodiversity. A long-term strategy is required to facilitate a better understanding of the treaties and the resulting opportunities for a fairer development and implementation of transparent national polices, which currently differ in the six countries. So far, the benefits envisioned by the CBD and the NP remain unfulfilled for all stakeholders involved including local communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.